Dupixent is a prescription medication that can help manage chronic inflammatory conditions in children, such as eczema, asthma, and eosinophilic esophagitis. It can be exhausting for a child to ...

Regeneron Pharmaceuticals REGN and its partner Sanofi SNY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion ...

What Is Dupixent, and Why Does It Matter? Dupixent (dupilumab) is a prescription medicine for treating various allergic conditions and is given as a shot under the skin. The FDA has now approved ...

Priority Review approval extends dupilumab into AFRS with prior surgery, expanding sino-nasal indications beyond CRSwNP and representing the ninth FDA-approved indication across type 2 inflammatory ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery ...

The patent for Dupixent, called the "miracle atopic dermatitis treatment," will expire around 2031. Dupixent was co-developed by French drugmaker Sanofi and U.S. biotech Regeneron and posted $14.1 ...

In the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatment Dupixent, which ...

Positive results from the pivotal LIBERTY-AFRS-AIMS phase 3 study (NCT04684524) evaluating the investigational use of Dupixent (dupilumab) in adults and children aged 6 years and older with allergic ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review Phase ...

Like any medication, Dupixent may cause various side effects. It’s especially known to cause side effects relating to the eyes, such as conjunctivitis, blepharitis, and keratitis. These side effects ...